COMMUNIQUÉS West-GlobeNewswire

Information on the total number of voting rights and shares

29/03/2024 - 21:30

REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), March 29, 2024 , 9:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the [...]

Informations sur le nombre total de droits de vote et d'actions

29/03/2024 - 21:30

INFORMATION RÉGLEMENTÉE Informations sur le nombre total de droits de vote et d'actions Mont-Saint-Guibert (Belgique), le 29 mars 2024, 21:30h CET / 16:30h ET – Conformément à l'article 15 de la loi du 2 mai 2007 [...]

AEON Biopharma Announces Redemption of Public Warrants

29/03/2024 - 21:15

IRVINE, Calif., March 29, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (NYSE: AEON; AEON.WS) (“AEON” or “the Company”), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin [...]

Avalo Reports 2023 Financial Results and Provides Business Updates

29/03/2024 - 21:01

Acquired AVTX-009, Phase-2 ready anti-IL-1β mAb, in March 2024 Increased cash position with private placement financing in March 2024 providing up to $185 million, including initial upfront investment of $115.6 million [...]

AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results

29/03/2024 - 20:45

– Recent end-of-Phase 2 meeting with FDA resulted in alignment on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraine – – Topline data from [...]

Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

29/03/2024 - 20:20

VIP236, first-in-class small molecule-drug conjugate (SMDC), preliminary Phase 1 data and update on pipeline progress will be presented by management at a virtual investor event on April 8 at 2:00 PM PT Phase 1 trial [...]

Range Impact Reports 4Q 2023 and Full Year 2023 Financial Results

29/03/2024 - 17:50

CLEVELAND, OHIO, March 29, 2024 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTC: RNGE) (“Range Impact”), a public impact investing company dedicated to acquiring, reclaiming and repurposing mine sites in Appalachia, [...]

NMDP Cycle Kicks Off Nationwide Cycling Events Giving Hope to Patients in Need of a Blood Stem Cell Transplant

29/03/2024 - 16:19

Riders can select from six routes to help raise funds and bring awareness to NMDP’s lifesaving mission MINNEAPOLIS, March 29, 2024 (GLOBE NEWSWIRE) -- NMDP SM Cycle (formerly Be The Match® Tour de TC) kicks off March 30 [...]

Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update

29/03/2024 - 14:00

- Data for masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) highlight best-in-class therapeutic index and demonstrate clinical benefits in metastatic microsatellite-stable (MSS) colorectal cancer (CRC) with higher, more [...]

Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates

29/03/2024 - 13:30

ELI-002 2P clinical immunogenicity data were accepted for a poster presentation at the AACR Annual Meeting 2024 ELI-007 and ELI-008 preclinical data were accepted for a poster presentation at the AACR Annual Meeting [...]

Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update

29/03/2024 - 13:21

AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of [...]

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

29/03/2024 - 13:00

-- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by year-end 2024 -- -- Exploring opportunities to expand KPI-012 into additional corneal indications -- -- Cash resources as of [...]

Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update

29/03/2024 - 13:00

NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business [...]

SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results

29/03/2024 - 12:15

Sioux Falls, SD , March 29, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results March 29, 2024 SAB-142 Phase 1 trial on track for data release during 2024 Completed [...]

Vision Sensing Acquisition Corp. Announces Intention to Extend Period to Consummate Initial Business Combination to May 3, 2024

29/03/2024 - 11:45

MIAMI, March 29, 2024 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “Company”) a special purpose acquisition company, announced today that it has notified Continental Stock [...]

Guardion Health Sciences Announces Financial Results for the Year Ended December 31, 2023

29/03/2024 - 11:15

Viactiv ® Product Line Generated Net Revenues of Approximately $11.9 Million for the Year Ended December 31, 2023, an Increase of Approximately 12% as Compared to the Year Ended December 31, 2022 HOUSTON, TEXAS, March [...]

Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development

29/03/2024 - 11:00

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, March 29, 2024 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the [...]

BioSenic S.A. : Information on the total number of voting rights and shares

29/03/2024 - 07:00

PRESS RELEASE – REGULATED INFORMATION Mont-Saint-Guibert, Belgium, March 29, 2024, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and [...]

BioSenic S.A. : Information relative au nombre total de droits de vote et d’actions

29/03/2024 - 07:00

COMMUNIQUE DE PRESSE – INFORMATION REGLEMENTEE Mont-Saint-Guibert, Belgique, le 29 mars 2024 à 07h00 CEST – BIOSENIC (Euronext Bruxelles et Paris: BIOS), la société en phase clinique spécialisée dans les maladies auto- [...]